Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health System, incoming vice president, American Academy of Dermatology (AAD), previews AAD 2022 and what she looks forward to both learning and teaching others.
Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health System, incoming vice president, American Academy of Dermatology (AAD), previews AAD 2022 and what she looks forward to both learning and teaching others.
Transcript
What are you most looking forward to at the 2022 American Academy of Dermatology Annual Meeting?
I'm looking forward to a lot of things at AAD 2022. First of all, I'm looking forward to seeing my colleagues in person and catching up. And I'm also looking forward to really getting educated on the latest data in medical, pediatric, and cosmetic dermatology.
What can attendees expect to learn at AAD 2022?
The meeting is going to be very comprehensive, with updates in all areas of dermatology. I personally will be chairing the acne and rosacea symposium and I'll begin giving an update on what's new in topical therapy. I'll be giving some updates on what's new in acne and rosacea in general. I'll also be talking about some of the latest breakthroughs in topical therapy for psoriasis and, in one interesting session, I'll be talking about the challenges of conducting clinical trials, and specifically the challenge of patient recruiting.
What are some of the big issues in dermatology that you hope to see addressed?
There are a lot of issues in dermatology right now and Academy leadership has so much on their plates, but I think they've been doing a really good job in tackling some of our main issues. Some of these include scope of practice battles, the cost of both treating and not treating our patients, the 2022 changes in MIPS [Merit-based Incentive Payment System] and MACRA [Medicare Access and CHIP Reauthorization Act], and also helping us to restore faith in iPLEDGE [Risk Evaluation and Mitigation Strategy program]. We're also making a major push for DEI [diversity, equity, and inclusion].
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More